Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for 908 Devices Inc. (NASDAQ: MASS) provides access to the company’s official U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain the contents of each document. As an emerging growth company listed on The NASDAQ Global Market, 908 Devices files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, among other documents.
In its filings, 908 Devices reports financial performance and segment details related to its portfolio of purpose-built handheld devices for chemical analysis. Investors can review product revenue, service and contract revenue, OEM and funded partnership revenue, recurring revenue associated with its installed base, and information on cost of revenue, operating expenses and net income or loss from continuing operations. The company also discloses non-GAAP metrics such as adjusted gross profit, adjusted gross margin and adjusted EBITDA, along with reconciliations to the nearest GAAP measures.
Form 8-K filings highlight material events such as quarterly earnings releases and changes in the Board of Directors. For example, recent 8-Ks have furnished press releases announcing financial results for specific quarters and documented the resignation of a director and appointment of a new director with extensive experience in nuclear, chemical and biological defense programs. These filings also confirm the company’s listing details and emerging growth company status.
Through this page, users can also monitor equity and governance disclosures, including information on non-employee director compensation, stock option and incentive plans, and any future insider transaction reports on Form 4 when available. Stock Titan’s AI tools summarize lengthy filings, highlight key figures and definitions, and surface important changes in revenue composition, operating expenses, contingent consideration, restructuring charges and other items that affect 908 Devices’ financial profile.
By combining real-time EDGAR updates with plain-language AI explanations, this filings hub helps readers quickly understand how 908 Devices is performing, how it uses non-GAAP measures, and how governance and strategic decisions are reflected in its regulatory record.
Christopher D. Brown filed an initial Statement of Beneficial Ownership (Form 3) for 908 Devices (MASS) following his appointment as Director. The filing reveals significant equity holdings as of June 13, 2025:
- Direct Common Stock ownership: 962,122 shares
- Stock Options: Total of 320,404 shares at various exercise prices ranging from $1.75 to $16.66, with different vesting schedules
- Restricted Stock Units (RSUs): 52,837 units vesting over four annual installments from 2022-2024
The stock options include both fully vested options and those with future vesting schedules through 2025. RSUs represent contingent rights to receive common stock upon vesting, with no expiration date. This substantial equity position aligns the director's interests with shareholders and indicates a long-term commitment to the company.
Michael S. Turner, Chief Legal & Administrative Officer of 908 Devices (MASS), executed a series of planned stock sales under a Rule 10b5-1 trading plan over three consecutive days in June 2025:
- June 16: Sold 16,082 shares at weighted average price of $7.5139
- June 17: Sold 7,148 shares at weighted average price of $7.506
- June 18: Sold remaining 1,373 shares at $7.50
The transactions resulted in a complete liquidation of Turner's direct common stock holdings, reducing his position from 24,603 shares to zero. All sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by determining the timing and terms of trades in advance.